We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen's Migraine Drug Hits Primary Endpoint in Phase IIIb
Read MoreHide Full Article
Amgen (AMGN - Free Report) announced that its fully human monoclonal antibody, Aimovig (erenumab), met all primary and secondary endpoints in a unique phase IIIb study for prevention of patients with episodic migraine, who have failed multiple prior preventive treatments.
Notably, Aimovig is the only investigational therapy designed to selectively block the calcitonin gene-related peptide (CGRP) receptor, which plays a significant role in migraine activation.
Aimovig is under review in both the United States and the EU for prevention of both episodic and chronic migraine. A decision from the FDA is expected on May 17, 2018.
Moreover, shares of the company are up 25.8% in a year, comparing favorably with the industry’s an increase of 8.6%.
The phase IIIb LIBERTY study was designed to evaluate the efficacy and safety of Aimovig in a broad spectrum of migraine patients ranging from those without a preventive treatment as well as those, who have tried and failed such therapies.
Results from the study demonstrated that at least 50% of patients achieved reduction of monthly migraine, days from the baseline over the last four weeks compared with placebo, the primary endpoint of the study. Data from the trial also showed consistent efficacy, safety and tolerability of Aimovig across a wider spectrum of migraine patients including those with complicated cases.
We remind investors that Amgen developed Aimovig in collaboration with Novartis (NVS - Free Report) . The companies have now agreed to combine capabilities to co-commercialize the candidate in the United States. Incidentally, Amgen retains its exclusive commercialization rights in Japan. Novartis, which retains its existing commercialization rights in rest of the world, has exclusive rights to commercialize Aimovig in Canada under the expanded deal.
Per the World Health Organization, migraine is one of the most debilitating illnesses. Approximately 10 million Americans’ daily activities are affected by frequency or severity of migraine. Around 3.5 million subjects are undergoing a preventive therapy, of which, 80% discontinues the treatment within a year. Hence, approval of Aimovig will provide the company a much-needed access to a huge patient population in the United States, who are in need of additional curative options to apprehend the disease.
However, several companies including Teva Pharmaceutical Industries Limited (TEVA - Free Report) and Allergan among others are also developing migraine treatments targeting CGRP.
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Amgen's Migraine Drug Hits Primary Endpoint in Phase IIIb
Amgen (AMGN - Free Report) announced that its fully human monoclonal antibody, Aimovig (erenumab), met all primary and secondary endpoints in a unique phase IIIb study for prevention of patients with episodic migraine, who have failed multiple prior preventive treatments.
Notably, Aimovig is the only investigational therapy designed to selectively block the calcitonin gene-related peptide (CGRP) receptor, which plays a significant role in migraine activation.
Aimovig is under review in both the United States and the EU for prevention of both episodic and chronic migraine. A decision from the FDA is expected on May 17, 2018.
Moreover, shares of the company are up 25.8% in a year, comparing favorably with the industry’s an increase of 8.6%.
The phase IIIb LIBERTY study was designed to evaluate the efficacy and safety of Aimovig in a broad spectrum of migraine patients ranging from those without a preventive treatment as well as those, who have tried and failed such therapies.
Results from the study demonstrated that at least 50% of patients achieved reduction of monthly migraine, days from the baseline over the last four weeks compared with placebo, the primary endpoint of the study. Data from the trial also showed consistent efficacy, safety and tolerability of Aimovig across a wider spectrum of migraine patients including those with complicated cases.
We remind investors that Amgen developed Aimovig in collaboration with Novartis (NVS - Free Report) . The companies have now agreed to combine capabilities to co-commercialize the candidate in the United States. Incidentally, Amgen retains its exclusive commercialization rights in Japan. Novartis, which retains its existing commercialization rights in rest of the world, has exclusive rights to commercialize Aimovig in Canada under the expanded deal.
Per the World Health Organization, migraine is one of the most debilitating illnesses. Approximately 10 million Americans’ daily activities are affected by frequency or severity of migraine. Around 3.5 million subjects are undergoing a preventive therapy, of which, 80% discontinues the treatment within a year. Hence, approval of Aimovig will provide the company a much-needed access to a huge patient population in the United States, who are in need of additional curative options to apprehend the disease.
However, several companies including Teva Pharmaceutical Industries Limited (TEVA - Free Report) and Allergan among others are also developing migraine treatments targeting CGRP.
Amgen Inc. Price
Amgen Inc. Price | Amgen Inc. Quote
Zacks Rank
Amgen carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>